MENU
BMRN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

BioMarin Pharmaceutical (BMRN) Earnings Date & Reports

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases... Show more

Industry: #Biotechnology
A.I. Advisor
published Earnings

BMRN is expected to report earnings to rise 8,650.00% to $1.75 per share on February 24

BioMarin Pharmaceutical BMRN Stock Earnings Reports
Q4'26
Est.
$1.75
Q3'26
Beat
by $0.32
Q2'26
Beat
by $0.25
Q1'26
Beat
by $0.02
Q4'25
Missed
by $0.31
The last earnings report on November 02 showed earnings per share of 1 cents, beating the estimate of -30 cents. With 3.49M shares outstanding, the current market capitalization sits at 10.85B.
A.I.Advisor
Nov 02, 2026

BioMarin Pharmaceutical (BMRN) Q3 2026 Earnings Recap: A Milestone Quarter and a Guidance Reset

Key Takeaways

  • BioMarin reported third-quarter 2026 total revenue of roughly $1.03 billion, up 32% year over year (Y/Y), topping $1 billion in a single quarter for the first time.
  • Non-GAAP (adjusted) diluted EPS (earnings per share) came in at $0.23, well above analyst consensus estimates.
  • Full-year 2026 revenue guidance was lowered to about $3.85 billion at the midpoint, citing order-timing uncertainty from a single international customer.
  • Full-year 2026 non-GAAP EPS guidance was reduced to $2.95 at the midpoint, a cut of roughly 41%.
  • Growth was led by the Metabolic Conditions franchise, up 44% Y/Y, while Voxzogo revenue rose 12% Y/Y to $245 million.
  • Shares slipped in after-hours trading as investors weighed the milestone revenue against the lowered outlook.
  • For more on BioMarin's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated BMRN pages.
  • Explore Trending AI Robots to see AI-driven trading strategies and market ideas.

Earnings Context and Why It Matters

BioMarin's third-quarter report carried unusual weight because it offered the first extended look at the company's post-acquisition profile. BioMarin completed its acquisition of Amicus Therapeutics earlier in 2026, adding Galafold (for Fabry disease) and Pombiliti + Opfolda (for Pompe disease) to its rare-disease portfolio. Investors were watching closely to see whether the deal would deliver the promised revenue diversification and cost synergies, and whether Voxzogo's growth in achondroplasia could keep momentum. With the company crossing the $1 billion quarterly-revenue threshold for the first time, the report confirmed meaningful scale, but a simultaneous reduction in full-year guidance highlighted lingering execution and timing risks heading into 2027.

Reported Results

BioMarin reported third-quarter 2026 total revenue of $1.025 billion, a 32% increase from the same period a year earlier and roughly in line with Wall Street consensus of about $1.02 billion. Non-GAAP diluted EPS (earnings per share) was $0.23, which beat analyst expectations.

The Metabolic Conditions franchise was the standout, generating $744 million in revenue, up 44% year over year. Within that segment, Galafold revenue reached $152 million (up 10% Y/Y), while Pombiliti + Opfolda contributed $49 million (up 58% Y/Y). On the skeletal side, Voxzogo revenue grew 12% Y/Y to $245 million, despite a large order shifting from the third quarter into the fourth.

Management updated full-year guidance, lowering the 2026 revenue midpoint to approximately $3.85 billion from $3.9 billion, reflecting uncertainty in the timing of multiple orders from a single international customer. Full-year non-GAAP diluted EPS guidance was reduced to $2.95 at the midpoint, a decrease of roughly 41% from the prior outlook.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like BioMarin, the tool offers a structured way to surface actionable setups across the market.

Market Reaction and Investor Sentiment

The market's response reflected a tension between a strong headline quarter and a softer outlook. While the $1 billion revenue milestone and the EPS beat underscored BioMarin's growing scale, the reduced full-year guidance tempered enthusiasm. Shares declined roughly 4% to 5% in after-hours trading following the announcement. The cut in adjusted EPS guidance—down about 41% at the midpoint—appeared to weigh most heavily on sentiment, as investors reassessed near-term profitability expectations. The order-timing uncertainty flagged in the Voxzogo and metabolic franchises also raised questions about quarterly revenue volatility, even as underlying patient demand remained solid.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several developments closely. First, the timing and magnitude of the deferred Voxzogo orders, particularly the large international order expected in the fourth quarter, will shape near-term revenue trends. Management noted that more than 75% of Voxzogo revenue now comes from outside the U.S., which increases exposure to order-timing swings.

Second, the integration of the Amicus portfolio remains a central theme. Cost synergies and the continued ramp of Galafold and Pombiliti + Opfolda will be key to whether the acquisition becomes accretive to earnings as management targets for 2027.

Third, pipeline catalysts could influence the narrative. Management pointed to the potential launch of Voxzogo in hypochondroplasia as a meaningful growth opportunity, along with a newly added investigational Fabry disease therapy that could become the first subcutaneous enzyme treatment for the condition.

Finally, margin trends and operating leverage will matter. With adjusted operating margins under pressure relative to historical levels, investors will be monitoring whether scale and integration efficiencies can restore profitability over time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of innovative pharmaceuticals for serious diseases & medical conditions

Industry Biotechnology

Industry
Biotechnology
Address
770 Lindaro Street
Phone
+1 415 506-6700
Employees
3221
Web
https://www.biomarin.com